Patents by Inventor Andreas Mantoulidis

Andreas Mantoulidis has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • 2,4-DIAMINO-PYRIMIDINES AS AURORA INHIBITORS
    Publication number: 20110251174
    Abstract: The present invention encompasses compounds of general formula (1) wherein R1 to R3 are defined as in claim 1, which are suitable for the treatment of diseases characterised by excessive or abnormal cell proliferation, and the use thereof for preparing a pharmaceutical composition having the above-mentioned properties.
    Type: Application
    Filed: June 14, 2011
    Publication date: October 13, 2011
    Applicant: BOEHRINGER INGELHEIM INTERNATIONAL GMBH
    Inventors: Stephan Karl ZAHN, Guido BOEHMELT, Andreas MANTOULIDIS, Ulrich REISER, Matthias TREU, Ulrich GUERTLER, Andreas SCHOOP, Flavio SOLCA, Ulrike TONTSCH-GRUNT, Ralph BRUECKNER, Charlotte REITHER, Lars HERFURTH, Oliver KRAEMER, Heinz STADTMUELLER, Harald ENGELHARDT
  • NEW CHEMICAL COMPOUNDS
    Publication number: 20110183952
    Abstract: The present invention encompasses compounds of general formula (1), wherein the groups R1 to R3 and L are defined as in claim 1, which are suitable for the treatment of diseases characterised by excessive or abnormal cell proliferation, and their use for preparing a medicament having the above-mentioned properties.
    Type: Application
    Filed: July 1, 2008
    Publication date: July 28, 2011
    Applicant: BOEHRINGER INGELHEIM INTERNATIONAL GMBH
    Inventors: Ioannis Sapountzis, Peter Ettmayer, Christian Klein, Andreas Mantoulidis, Steffen Steurer, Irene Waizenegger
  • 3-(aminomethyliden) 2-indolinone derivates and their use as cell proliferation inhibitors
    Patent number: 7981880
    Abstract: The present invention encompasses compounds of general formula (1) wherein R1, R2, R3 and X are defined as in claim 1, which are suitable for the treatment of diseases characterised by excessive or abnormal cell proliferation, and the use thereof for preparing a pharmaceutical composition having the above-mentioned properties.
    Type: Grant
    Filed: April 23, 2007
    Date of Patent: July 19, 2011
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Matthias Treu, Andreas Mantoulidis, Ulrike Tontsch-Grunt
  • NEW CHEMICAL COMPOUNDS
    Publication number: 20110059938
    Abstract: The present invention encompasses compounds of general formula (1) wherein the groups R2 to R4, L, Q and n are defined as in claim 1, which are suitable for the treatment of diseases characterised by excessive or abnormal cell proliferation, and the use thereof for preparing a medicament having the above-mentioned properties.
    Type: Application
    Filed: November 15, 2010
    Publication date: March 10, 2011
    Applicant: BOEHRINGER INGELHEIM INTERNATIONAL GMBH
    Inventors: Steffen STEURER, Peter ETTMAYER, Andreas MANTOULIDIS, Ioannis SAPOUNTZIS, Martin STEEGMAIER
  • CHEMICAL COMPOUNDS
    Publication number: 20100240657
    Abstract: The present invention encompasses compounds of general formula (1) wherein the groups R2 to R4, L, Q and n are defined as in claim 1, which are suitable for the treatment of diseases characterised by excessive or abnormal cell proliferation, and their use for preparing a pharmaceutical composition with the above-mentioned properties.
    Type: Application
    Filed: July 1, 2008
    Publication date: September 23, 2010
    Applicant: BOEHRINGER INGELHEIM INTERNATIONAL GMBH
    Inventors: Ioannis Sapountzis, Peter Ettmayer, Christian Klein, Andreas Mantoulidis, Martin Steegmaier, Steffen Steurer, Irene Waizenegger
  • Compounds
    Publication number: 20100144706
    Abstract: The present invention encompasses compounds of general formula (1) wherein R1 to R4, X and n are defined as in claim 1, which are suitable for the treatment of ailments characterised by excessive or abnormal cell proliferation, and the use thereof for preparing a medicament having the above-mentioned properties.
    Type: Application
    Filed: December 20, 2007
    Publication date: June 10, 2010
    Applicant: BOEHRINGER INGELHEIM INTERNATIONAL GMBH
    Inventors: Stephan Karl Zahn, Guido Boehmelt, Ulrich Guertler, Andreas Mantoulidis, Andreas Schoop, Flavio Solca, Ulrike Tontsch-Grunt, Matthias Treu
  • New compounds
    Publication number: 20090163467
    Abstract: The present invention encompasses compounds of general formula (1) wherein R1, R2, R4, X, m, n and p are defined as in claim 1, which are suitable for the treatment of diseases characterised by excessive or abnormal cell proliferation, and their use for preparing a pharmaceutical composition having the above-mentioned properties.
    Type: Application
    Filed: May 11, 2007
    Publication date: June 25, 2009
    Inventors: Stephan Karl Zahn, Bojan Bister, Guido Boehmelt, Ulrich Guertler, Andreas Mantoulidis, Ulrich Reiser, Andreas Schoop, Flavio Solca, Ulrike Tontsch-Grunt, Matthias Treu
  • 3- (AMINOMETHYLIDEN) 2-INDOLINONE DERIVATES AND THEIR USE AS CELL PROLIFERATION INHIBITORS
    Publication number: 20090105216
    Abstract: The present invention encompasses compounds of general formula (1) wherein R1, R2, R3 and X are defined as in claim 1, which are suitable for the treatment of diseases characterised by excessive or abnormal cell proliferation, and the use thereof for preparing a pharmaceutical composition having the above-mentioned properties.
    Type: Application
    Filed: April 23, 2007
    Publication date: April 23, 2009
    Inventors: Matthias Treu, Andreas Mantoulidis, Ulrike Tontsch-Grunt
  • NEW CHEMICAL COMPOUNDS
    Publication number: 20080182837
    Abstract: The present invention encompasses compounds of general formula (1) wherein the groups R2 to R4, L, Q and n are defined as in claim 1, which are suitable for the treatment of diseases characterised by excessive or abnormal cell proliferation, and the use thereof for preparing a medicament having the above-mentioned properties.
    Type: Application
    Filed: July 5, 2007
    Publication date: July 31, 2008
    Inventors: Steffen STEURER, Peter Ettmayer, Andreas Mantoulidis, loannis Sapountzis, Martin Steegmaier
  • 2,4-diamino-pyrimidines as aurora inhibitors
    Publication number: 20070032514
    Abstract: The present invention encompasses compounds of general formula (1) wherein R1 to R3 are defined as in claim 1, which are suitable for the treatment of diseases characterised by excessive or abnormal cell proliferation, and the use thereof for preparing a pharmaceutical composition having the above-mentioned properties.
    Type: Application
    Filed: June 27, 2006
    Publication date: February 8, 2007
    Inventors: Stephan Zahn, Guido Boehmelt, Andreas Mantoulidis, Ulrich Reiser, Matthias Treu, Ulrich Guertler, Andreas Schoop, Flavio Solca, Ulrike Tontsch-Grunt, Ralph Brueckner, Charlotte Reither, Lars Herfurth, Oliver Kraemer, Heinz Stadtmueller, Harald Engelhardt
  • Alpha-Carbolines as CDK-1 inhibitors
    Publication number: 20070004684
    Abstract: The present invention encompasses compounds of general formula (1) wherein R2 to R5 and X are defined as in claim 1, which are suitable for the treatment of diseases characterised by excessive or abnormal cell proliferation, and the use thereof for preparing a pharmaceutical composition having the above-mentioned properties.
    Type: Application
    Filed: June 8, 2006
    Publication date: January 4, 2007
    Applicant: Boehringer Ingelheim International GmbH
    Inventors: Peter Sennhenn, Andreas Mantoulidis, Matthias Treu, Ulrike Tontsch-Grunt, Walter Spevak, Darryl McConnell, Andreas Schoop, Ralph Brueckner, Albrecht Jacobi, Ulrich Guertler, Gisela Schnapp, Christian Klein, Frank Himmelsbach, Alexander Pautsch, Bodo Betzmeier, Lars Herfurth, Juergen Mack, Dieter Wiedenmayer, Gerd Bader, Ulrich Reiser
  • Method for producing epothilone B and derivatives, and intermediate products for this method
    Publication number: 20030220503
    Abstract: This invention relates to a process for the production of epothilone B and derivatives as well as intermediate products for this process. In the new process, epothilone B or the derivatives are built up in high yields from the C1-C6, C7-C10 and C11-C20 fragments (2, 3 and 4) that can be obtained at a reasonable price and free of diastereomers (the variable radicals have the meanings that are indicated in the description).
    Type: Application
    Filed: April 23, 2003
    Publication date: November 27, 2003
    Applicant: Schering Aktiengesellschaft
    Inventors: Johann Mulzer, Andreas Mantoulidis, Elisabeth Ohler
  • Method for producing epothilone B and derivatives, and intermediate products for this method
    Patent number: 6605726
    Abstract: The invention relates to a method for producing epothilone B and derivatives, and to intermediate products for this method. According to the novel method, the epothilone B or derivatives are produced in high yields from the C1-C6, C7-C10 and C11-C20-fragments 2, 3 and 4 that can be obtained economically and diastereomerically purely (the variable radicals having the meanings given in the description ).
    Type: Grant
    Filed: June 1, 2001
    Date of Patent: August 12, 2003
    Assignee: Schering AG
    Inventors: Johann Mulzer, Andreas Mantoulidis, Elisabeth Öhler